Related Experiment Video
Updated: Jun 12, 2026
05:39
Murine Model of Wound Healing
Published on: May 28, 2013
Accelerated wound healing by mTOR activation in genetically defined mouse models.
Cristiane H Squarize1, Rogerio M Castilho, Thomas H Bugge
1Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States of America.
Plos One
|May 26, 2010
Summary
Activating the PI3K-Akt-mTOR pathway speeds up wound healing by boosting cell growth and migration. This discovery offers a new strategy for treating chronic wounds, especially in diabetic patients.
Area of Science:
- Cell Biology
- Molecular Biology
- Dermatology
Background:
- Chronic wound management is a growing challenge due to aging populations and rising type II diabetes rates.
- Tumor growth pathways are being investigated for their potential role in tissue regeneration.
- Novel molecular targets are sought to accelerate wound healing.
Purpose of the Study:
- To investigate the role of the PI3K-Akt-mTOR pathway in wound healing.
- To identify molecular targets for accelerating tissue repair.
Main Methods:
- Utilized genetically modified mouse models with epithelial-specific ablation of Pten and Tsc1.
- Examined the effects of mTOR activation and inhibition on epithelial cell behavior and wound closure.
- Investigated the PI3K-Akt-mTOR pathway's role in cutaneous wound healing.
Main Results:
- Activation of the PI3K-Akt-mTOR pathway is crucial for normal wound healing.
- mTOR activation significantly enhances epithelial cell proliferation, migration, and accelerates cutaneous wound healing.
- Pharmacological inhibition of mTOR with rapamycin impedes wound closure.
Conclusions:
- Transient activation of the PI3K-Akt-mTOR signaling axis presents a novel therapeutic strategy.
- This approach could accelerate the healing of severe and life-threatening wounds.
- Findings offer a new avenue for clinical intervention in wound care.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:43Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...